Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib with FOLFOXIRI/bevacizumab in metastatic colorectal cancer
CTR20211298Phase 3Terminated
- Sponsor
- G1 Therapeutics, Inc.
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trilaciclib in metastatic colon cancer (mCRC), sponsored by G1 Therapeutics, Inc.. Started Jun 2021; status: terminated.
02
Drugs
trilaciclib
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on CTR20211298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211298.